Amendments to the Claims under 37 C.F.R. § 1.121

Claims 1-22 (cancelled).

Claim 23 (currently amended): A method for ameliorating the harmful effects of TNF in an

animal, comprising administering to an animal in need of such treatment a therapeutically

effective amount of an isolated recombinant-polypeptide having the ability to bind TNF, wherein

said polypeptide is not associated with human urinary proteins, and wherein said polypeptide

comprises the amino acid sequence as set forth in SEQ ID NO: 4.

Claims 24-40 (cancelled).

Claim 41 (currently amended): A method for ameliorating the harmful effects of TNF in an

animal, comprising administering to an animal in need of such treatment a therapeutically

effective amount of an isolated recombinant-polypeptide having the ability to bind TNF, wherein

said polypeptide is not associated with human urinary proteins, and wherein said polypeptide

consists of the amino acid sequence of SEQ ID NO: 4.

Claims 42-44 (cancelled).

Claim 45 (previously presented): The method of Claim 23, wherein said polypeptide has at

least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the

amino-terminus and the carboxyl-terminus.

Claim 46 (original): The method of Claim 45, wherein said polypeptide has at least one

additional amino acid at the amino-terminus.

Claim 47 (cancelled).

Claim 48 (original): The method of Claim 45, wherein said polypeptide has at least one

2

additional amino acid at the carboxyl-terminus.

Claim 49 (cancelled).

Claim 50 (currently amended): The method of either Claim 1 or 23, wherein said polypeptide is chemically derivatized.

Claims 51-59 (cancelled).